CN110997715A - 用于治疗突触核蛋白病的组合物和方法 - Google Patents

用于治疗突触核蛋白病的组合物和方法 Download PDF

Info

Publication number
CN110997715A
CN110997715A CN201880026858.1A CN201880026858A CN110997715A CN 110997715 A CN110997715 A CN 110997715A CN 201880026858 A CN201880026858 A CN 201880026858A CN 110997715 A CN110997715 A CN 110997715A
Authority
CN
China
Prior art keywords
seq
amino acid
synuclein
alpha
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880026858.1A
Other languages
English (en)
Chinese (zh)
Inventor
N.彭纳
K.K.穆拉里德哈兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen International Neuroscience GmbH
Original Assignee
Biogen International Neuroscience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen International Neuroscience GmbH filed Critical Biogen International Neuroscience GmbH
Publication of CN110997715A publication Critical patent/CN110997715A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880026858.1A 2017-03-31 2018-03-30 用于治疗突触核蛋白病的组合物和方法 Pending CN110997715A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762479818P 2017-03-31 2017-03-31
US62/479,818 2017-03-31
US201762528790P 2017-07-05 2017-07-05
US62/528,790 2017-07-05
PCT/IB2018/052236 WO2018178950A1 (en) 2017-03-31 2018-03-30 Compositions and methods for treating synucleinopathies

Publications (1)

Publication Number Publication Date
CN110997715A true CN110997715A (zh) 2020-04-10

Family

ID=62092178

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880026858.1A Pending CN110997715A (zh) 2017-03-31 2018-03-30 用于治疗突触核蛋白病的组合物和方法

Country Status (13)

Country Link
US (1) US20200377579A1 (https=)
EP (1) EP3630815A1 (https=)
JP (1) JP2020512368A (https=)
KR (1) KR20200026789A (https=)
CN (1) CN110997715A (https=)
AU (1) AU2018242626A1 (https=)
BR (1) BR112019020335A2 (https=)
CA (1) CA3058304A1 (https=)
IL (1) IL269637A (https=)
JO (1) JOP20190227A1 (https=)
MA (1) MA48730A (https=)
SG (1) SG11201908672WA (https=)
WO (1) WO2018178950A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
JP2021502955A (ja) * 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
US20190153102A1 (en) 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2020079113A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
CA3159964A1 (en) * 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
IL301039A (en) 2020-09-10 2023-05-01 Prothena Biosciences Ltd Treatment of parkinson's disease
KR20240055758A (ko) 2021-09-16 2024-04-29 하. 룬드벡 아크티에셀스카브 시누클레인병증을 치료하기 위한 조성물 및 방법
WO2024167821A2 (en) * 2023-02-06 2024-08-15 Creative Bio-Peptides, Inc. Peptides for treating neurological disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317316A (zh) * 2008-12-19 2012-01-11 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
CN104822389A (zh) * 2012-10-08 2015-08-05 普罗典娜生物科学有限公司 识别α-突触核蛋白的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
HUE041391T2 (hu) * 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317316A (zh) * 2008-12-19 2012-01-11 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
CN104822389A (zh) * 2012-10-08 2015-08-05 普罗典娜生物科学有限公司 识别α-突触核蛋白的抗体

Also Published As

Publication number Publication date
WO2018178950A1 (en) 2018-10-04
JP2020512368A (ja) 2020-04-23
JOP20190227A1 (ar) 2019-09-30
IL269637A (en) 2019-11-28
US20200377579A1 (en) 2020-12-03
CA3058304A1 (en) 2018-10-04
BR112019020335A2 (pt) 2020-04-28
AU2018242626A1 (en) 2019-10-10
EP3630815A1 (en) 2020-04-08
KR20200026789A (ko) 2020-03-11
MA48730A (fr) 2020-04-08
SG11201908672WA (en) 2019-10-30

Similar Documents

Publication Publication Date Title
CN110997715A (zh) 用于治疗突触核蛋白病的组合物和方法
US12145988B2 (en) Anti-TREM-2 agonist antibodies
KR101774121B1 (ko) 이중특이적 항-vegf/항-ang-2 항체 및 안 혈관 질환의 치료에 있어서 이의 용도
US12247985B2 (en) Methods of detecting transthyretin
US20120148591A1 (en) Antibodies That Bind Amyloid Oligomers
CA2974993A1 (en) Anti-transthyretin antibodies
CA3073066A1 (en) Pharmaceutical compositions containing anti-beta amyloid antibodies
KR20200033880A (ko) 항체 결합 활성 알파 시누클레인
US12116407B2 (en) Methods of treating neurodegenerative diseases
AU2017418317A1 (en) Compositions and methods for treating tauopathies
AU2019371814A1 (en) Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
KR20240115910A (ko) 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법
KR20230093499A (ko) 인간 대상체에서 타우를 감소시키는 방법
WO2020077380A1 (en) Methods and compositions for treating tauopathies
WO2017050955A1 (en) Agents capable of inhibiting the binding between leptin and vegf165
JPWO2023156549A5 (https=)
US20190135905A1 (en) Compositions and methods for treating tauopathies
KR20260042555A (ko) 알츠하이머병 치료제의 개발 및 용도
JP2026504928A (ja) Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法
IL305161A (en) Methods of using TAU detection antibodies
NZ789385A (en) Compositions and methods for treating tauopathies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200410

WD01 Invention patent application deemed withdrawn after publication